Sensitivity of the ProC® Global assay for protein C pathway abnormalities. Clinical experience in 899 unselected patients with venous thromboembolism

Thrombosis Research

Volumn 104, Issue 2, 2001, Pages 93-103

  Toulon, P ^a   Adda, R ^a   Perez, P ^a  

^a Hôpital Cochin ^*  (France)

Author keywords

APC resistance; Deficiency; Factor V Leiden; Protein C; Protein S; Screening; Thrombophilia

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; PROTEIN S; FIBRINOLYTIC AGENT; PROTEIN C;

ADULT; AGED; ANAMNESIS; ARTICLE; ASSAY; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVICE; ENZYME ACTIVATION; FEMALE; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; TIME; ADOLESCENT; BLOOD; BLOOD CLOTTING TEST; CHILD; EVALUATION; INFANT; METABOLISM; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; ROC CURVE; STANDARD; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION TESTS; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFANT; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; PROTEIN C; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0035886018     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(01)00361-9     Document Type: Article

References (48)

1. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
2. Mutation in blood coagulation factor V associated with resistance to activated protein C
3. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study
4. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
5. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management
6. World distribution of factor V Leiden
7. Myocardial infarction, Arg 506 to Gln mutation and activated protein C resistance
8. High prevalence of the FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis
9. Inherited thrombophilia: Part 1
10. Inherited thrombophilia: Part 2
11. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma
12. The PCAT - A simple screening assay for assessing the functionality of the protein C anticoagulant pathway
13. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S
14. Anticoagulant response to Agkistrodon contortrix venom (ACV) test: A new global test to screen for defects in the anticoagulant protein C pathway
15. A new global test for the evaluation of the protein C-protein S system
16. A Protac®-based screening test for activated protein C-resistant factor Va and other defects of the protein C anticoagulant pathway
17. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies
18. Screening for abnormalities of the protein C anticoagulant pathway using the Protein C Pathway Test
19. ProC® Global: The first functional screening assay for the complete protein C pathway
20. Evaluation of a new screening assay ProC® Global for identification of defects in the protein C/protein S anticoagulant pathway
21. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway
22. Screening for abnormalities of the protein C anticoagulant pathway using the ProC® Global assay. Results of a European multicenter trial
23. The anticoagulant potential of the protein C system in hereditary and acquired thrombophilia: Pathomechanisms and new tools for assessing its clinical relevance
24. ProC® Global, a new assay to evaluate the functionality of the protein C anticoagulant pathway. Preliminary results in 223 consecutive patients with a history of venous thromboembolism
25. Changes in the plasma levels of vitamin K-dependent proteins C and S and C4b-binding protein during pregnancy and oral contraception
26. Oral contraceptives and gender affect protein S status
27. Effect of oral contraceptives on haemostasis variables
28. Protein S deficiency and HIV infection
29. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals
30. A rapid screening method for the factor V Arg→Gln mutation
31. Fast functional protein C assay using Protac®, a novel protein C activator
32. New direct assay for free protein S antigen using two distinct monoclonal antibodies specific for the free form
33. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France
34. Criteria for the diagnosis of lupus anticoagulants: An update
35. Basic principles of ROC analysis
36. A modified functional global test to measure protein C, protein S activities and the activated protein C-resistance phenotype
37. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
38. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: Role of increased synthesis and relationship to the acute phase reaction
39. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
40. Elevation of factor VIII:C in venous thromboembolism is persistent and independent of the acute phase response
41. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium: I. Normal condition
42. Haemostasis in normal pregnancy
43. Cutaneous and plasma values of von Willebrand factor in AIDS: A marker of endothelial stimulation?
44. Oral contraceptives and venous thromboembolism: Acquired APC resistance?
45. Effect of oral contraceptives on haemostasis variables
46. Venous thrombosis, oral contraceptives and high factor VIII levels
47. ProC® Global assay is an independent predictor for venous thromboembolism
48. ProC® Global screening test and the risk of thrombosis